Dermato®brosarcoma protuberans (DP), an in®ltrative skin tumour of intermediate malignancy, presents speci®c cytogenetic features such as reciprocal translocations t(17;22)(q22;q13.1) or supernumerary ring chromosomes derived from t(17;22). We have previously shown that both rings and translocated chromosomes derived from t(17;22) presented the same molecular rearrangement with fusion of the COL1A1 gene on chromosome 17 to the PDGFB gene on chromosome 22. To study the structure and function of the COL1A1 ± PDGFB chimeric protein, we used a tumour-derived chimeric COL1A1 ± PDGFB cDNA to perform stable and transient transfections in the Chinese hamster lung ®broblastic cell line PS200 and the human epithelial cell line HEK293. We demonstrated that the stably transfected clones that expressed the COL1A1 ± PDGFB chimeric protein became growth factors independent and tumorigenic in nude mice. In addition, COL1A1 ± PDGFB transfected cell supernatants signi®cantly stimulated ®broblastic cell growth, through the activation of the PDGFB receptor pathway. By using anti-PDGFB and speci®c anti-COL1A1 ± PDGFB antibodies, we showed that, similar to PDGFB, the COL1A1 ± PDGFB chimeric proteins are processed in transfected cells into mature PDGFB dimers. These results strongly suggest that the COL1A1 ± PDGFB chimeric gene expression associated with DP, induces tumours formation through production of mature PDGFB, in an autocrine or paracrine way. Strikingly, mutagenesis experiments indicated that uncleaved COL1A1 ± PDGFB forms are mitogenic and therefore could contribute, as well as mature PDGFB, to the establishment of a transformed phenotype. Oncogene (2001) 20, 2965 ± 2975.
Introduction
Dermato®brosarcoma protuberans (DP) is an in®ltra-tive tumour of the deep dermis. These tumours are locally aggressive and highly recurrent, but metastases or tumour-related deaths are extremely rare (Enzinger and Weiss, 1995; Fish, 1996; Mentzel et al., 1998) . DP presents speci®c cytogenetic features such as reciprocal translocations t(17;22)(q22;q13.1) or more often, supernumerary ring chromosomes derived from t(17;22) (Pedeutour et al., 1995 (Pedeutour et al., , 1996 . In most DP cases, the derivative chromosome 17 was not present. In contrast, several copies of the derivative chromosome 22 were generally observed. We have previously shown that both rings and translocated chromosomes present the same molecular rearrangement that fuses the collagen type 1 alpha 1 (COL1A1) gene on chromosome 17 to the platelet-derived growth factor B chain gene (PDGFB) on chromosome 22 (Simon et al., 1997) .
Type 1 collagen, the major component of the extra cellular matrix, is a heterotrimer composed of two a1(l) chains and one a2(l) chain encoded by COL1A1 and COL1A2 genes, respectively (Dalgleish, 1997) . PDGFB gene encodes the B chain of PDGF and is the cellular homologue of the v-sis oncogene, which is known to cause simian sarcoma (Doolittle et al., 1983; Water®eld et al., 1983) . PDGFB, a homodimer composed of two B chains, is a potent mitogen for a variety of cells (Heldin et al., 1998) . Although the contribution of PDGFB in tumour genesis is not fully clari®ed, the coexpression of PFGFB and its receptors has been described in many tumours, including DP, and the possibility of autocrine PDGFB stimulation in these tumours has been suggested (Smits et al., 1992; Kikuchi et al., 1993; Westermark and Sorg, 1993) .
To date, in all DP cases studied, the t(17;22) translocation resulted in chimeric COL1A1 ± PDGFB RNA production, in which the PDGFB exon 1 was deleted and replaced by a variable segment of COL1A1 gene (Simon et al., 1997; Greco et al., 1998; Navarro et al., 1998; O'Brien et al., 1998; Wang et al., 1999) . To our knowledge, the reciprocal PDGFB ± COL1A1 transcripts have never been described in the 35 cases of DP studied to date, suggesting a preponderant role for the COL1A1 ± PDGFB fusion gene.
As a consequence of the t(17;22), the sequences located upstream of PDGFB exon 2, which are known to contain repressor elements for PDGFB transcription and translation are replaced by COL1A1 elements. The loss of PDGFB exon 1 is responsible for v-sis oncogene activation in experimental models (Rao et al., 1988; Dirks et al., 1993) . Therefore, one could assume that the t(17;22) rearrangement causes the production of an autocrine COL1A1 ± PDGFB growth factor responsible for DP development.
Studies on chimeric COL1A1 ± PDGFB RNA have shown that fusion points are widely variable on the COL1A1 sequence, from exon 7 to exon 47 (O'Brien et al., 1998; Wang et al., 1999) . This could indicate that COL1A1 sequences play a subordinate role in the COL1A1 ± PDGFB protein and are not essential for the potential growth factor activity. In contrast, COL1A1 ± PDGFB fusions always preserves PDGFB sequences, allowing for synthesis of mature PDGFB protein from the N to the C terminus cleavage sites encoded by exons 3 and 6, respectively (Westermark and Sorg, 1993) . Therefore, it could be hypothesized that the contribution of COL1A1 to the chimeric protein would only be to provide the signal peptide essential for protein export. In similarity to the processing of wild type PDGFB, the processing of the COL1A1 ± PDGFB chimeric proteins would further result in the production of mature PDGFB in the tumour cells. To validate this hypothesis, we generated ®broblastic cell lines expressing a DP-derived COL1A1 ± PDGFB gene fusion. In this report, we present the structural and functional characterisation of the COL1A1 ± PDGFB proteins synthesized in COL1A1 ± PDGFB expressing cells.
Results

Generation of mutant COL1A1 ± PDGFB cDNA
A chimeric COL1A1 ± PDGFB cDNA sequence of the COL1A1 exon 29 fused to PDGFB exon 2 was isolated from the DP T94796 tumour and cloned in the pcDNA3.1 expression vector (Figure 1a ). COL1A1 and PDGFB are both encoded as pro-peptides, which are processed by proteolytic cleavage at the N-and Ctermini, to give mature proteins (Royce and Steinmann, 1993; Westermark and Sorg, 1993) . The T94796 COL1A1 ± PDGFB chimeric protein sequence retained the COL1A1 N-terminal processing site and the N and C-terminal PDGFB processing sites (Figure 1b,c) . The COL1A1 N-terminal cleavage site, encoded by COL1A1 exon 6, corresponds to the COL1A1 Nterminus propeptide removal, immediately following proline 161. The N-and C-terminal PDGFB processing sites, encoded by PDGFB exons 3 and 6, correspond respectively to the PDGFB N-and Ctermini propeptides cleavages, immediately following arginine 721 and threonine 830. We obtained two single mutated pcDNA3.1-T94796 constructions named C5 and P5, with a mutation at the COL1A1 Nterminal cleavage site and at the PDGFB N-terminal cleavage site, respectively. The C5 C to G mutation, resulted in substitution of proline 161 for alanine, and the P5 A to G mutation, resulted in substitution of arginine 721 for glycine. The wild type pcDNA3.1-T94796 (WT) and the mutant constructions C5 and P5 were transiently transfected in the HEK293 cell line.
The chimeric COL1A1 ± PDGFB protein is processed into PDGFB in transfected cells
The proteins encoded by the T94796 COL1A1 ± PDGFB fusion sequence in transfected cells were analysed by Western blotting using anti-PDGFB or anti-COL1A1 ± PDGFB antibodies, which speci®cally recognize the fusion protein.
In non-reducing conditions, anti-COL1A1-PDGFB antiserum recognized high molecular forms (up to 200 kD) in stably transfected cells lysates (Figure 2a arrow). These forms, when reduced in the presence of bME, migrate as a band at 116 kD (Figure 2a, arrowhead) , suggesting that these 116 kD chains associate as dimers. In the extra cellular media, the 116 kD band was not detected. Instead, a major 100 kD size component was detected and most likely resulted from the cleavage of the 116 kD chain (Figure 2a, star) .
These results suggested that the chimeric COL1A1 ± PDGFB proteins coded by the T94796 COL1A1 ± PDGFB cDNA were initially expressed in cells as 116 kD chains associated in dimers and were further processed by proteolytic cleavage. To investigate more precisely the processing of the chimeric COL1A1 ± PDGFB proteins, we analysed in transient transfection assays the proteins encoded by the two single COL1A1 ± PDGFB mutant cDNA constructions C5 and P5 compared to the proteins produced by the wild type (WT) COL1A1 ± PDGFB pcDNA3.1-T94796 construction or the pcDNA3.1 empty vector (C).
As in stable COL1A1 ± PDGFB expressing clones, the anti-COL1A1 ± PDGFB antiserum recognized forms of 100 kD in the wild type pcDNA3.1 ± T94796 HEK293 transfected cells media (Figure 2b , lane WT, star). These 100 kD forms were also detected in the mutated C5 vector transfected cells media (Figure 2b , lane C5, star) but not in the mutated P5 vector transfected cells media. Instead we found components of 116 kD (Figure 2b, lane P5, arrowhead) .
In addition, anti-PDGFB antiserum recognized in wild type pcDNA3.1 ± T94796 HEK293 transfected cell media as well as in mutated C5 transfected cell media, a 30 kD form that co-migrated with commercial PDGF-BB dimers (Figure 2c, arrowheads) . Interestingly, these 30 kD forms were absent in the media of cells transfected with mutated P5 construction and instead high molecular forms recognized by both anti-PDGFB and anti-COL1A1 ± PDGFB antisera were detected (Figure 2b, c, arrows) . These 30 kD PDGFBlike species were also detected with the anti-PDGFB antiserum in the extra cellular media prepared from stably transfected cell lines XI and XVI (data not shown).
These results demonstrate that COL1A1 ± PDGFB transfected cells produce PDGFB-like molecules in the extracellular medium. Since the P5 mutation prevented both the COL1A1 ± PDGFB 100 kD chain and PDGFB dimers production and led to the accumulation of COL1A1 ± PDGFB 116 kD chains in the media, we assumed that the production of PDGFB molecules in COL1A1 ± PDGFB expressing cells directly resulted from cleavage of the 116 kD chains at the putative PDGFB N-terminal processing site. The description of PDGFB maturation is well documented (Westermark and Sorg, 1993) . PDGFB is produced in cells, as a 241 amino acid proteins that form dimers of 56 kD. These dimers are ®rst processed by N-terminal proteolytic cleavage to give membrane-associated 35 ± 40 kD dimers. A subset of them is then cleaved at the C- Deduced chimeric COL1A1 ± PDGFB protein map compared to wild type COL1A1 and PDGFB proteins. The COL1A1 sequence is indicated in light grey and the PDGFB sequence in dark grey. The black and white boxes indicate the COL1A1 and PDGFB signal peptides sequences, respectively. Arrows indicate mutation points on the COL1A1 ± PDGFB sequence and arrowheads indicate the proteolytic cleavage sites. C5 and P5 refer to respective mutated pcDNA3.1 ± T94796 constructions. Numbers at the left of the arrowheads indicate the amino acid position on the chimeric COL1A1 ± PDGFB protein sequence, which begins at the ®rst methionine of the consensus COL1A1 sequence terminus to give 30 kD dimers, which constitute the secreted form of PDGFB (Ostman et al., 1992) . Our results suggest that a similar mechanism of dimerisation followed by proteolytic cleavage occurred in COL1A1 ± PDGFB transfected cells; they processed the 116 kD size COL1A/PDGFB expressed chains into 30 kD PDGFB secreted mature dimers. The C5 mutation had no detectable eect either on the 116 kD chain or on the PDGFB production. Since the C5 site mutation was ineective, we supposed that the COL1A1 N-terminal cleavage site is not crucial in COL1A1 ± PDGFB 116 kD chain processing.
Mitogenic potential of chimeric COL1A1-PDGFB proteins
CCL39 and its derivative PS200 cells are known to be highly dependent upon growth factors for reinitiation of DNA synthesis (Perez-Rodriguez et al., 1981) . Uncontrolled production of PDGFB in COL1A1 ± Figure 2 Immuno-detection of COL1A1 ± PDGFB chimeric proteins in COL1A1 ± PDGFB expressing cells. Proteins from PS200 stably transfected cell lines (a) and from transient HEK293 transfected cells (b and c) were analysed by SDS ± PAGE in reducing (+bME) or non-reducing (7bME) conditions and probed with speci®c anti-COL1A1 ± PDGFB (a and b) or anti-PDGFB antibodies (c). Proteins were prepared from total lysates (ly) or extracellular media (me). (a) PS200 cells lines stably transfected with the pcDNA 3.1 empty vector as a control (clone Co) or with the pcDNA3.1-T94796 construction (clones XI and XVI). (b and c) HEK293 cells transiently transfected with pcDNA 3.1 empty vector, as a control (lane C) or with wild type (lane WT) and mutant (lanes C5 and P5) pcDNA3.1 ± T94796 constructions PDGFB transfected cells was expected to relax the growth factor requirement for DNA synthesis. Therefore, we measured the dose-response of FCS or PDGFB-induced reinitiation of DNA synthesis in PS200 COL1A1 ± PDGFB stably transfected clones. In contrast to empty vector transfected PS200 cells, the dose-responses were markedly shifted to the left for transfected clones XI and XVI (Figure 3a,b) . Compared to control cells, the EC 50 (serum or PDGFB concentrations giving half of the maximal response) decreased signi®cantly for clone XVI, while clone XI cells failed to respond to FCS and PDGFB. In addition, high rates of thymidine incorporation (35% for clone XVI and up to 90% for clone XI), in total absence of serum or PDGFB stimulation, indicated that a large proportion of cells expressing COL1A1 ± PDGFB were permanently cycling in absence of exogenous growth factors. These results suggest that constitutive COL1A1 ± PDGFB protein expression in transfected cells disrupts growth control and allows for autonomous cell cycling. To more precisely investigate the mitogenic potential of COL1A1 ± PDGFB secreted proteins in COL1A1 ± PDGFB transfected cells, we tested serum-free conditioned media on reinitiation of DNA synthesis (Figure 4) . Our results showed that compared to empty vector control clone Co, supernatants from COL1A1 ± PDGFB stably transfected clones XI and XVI signi®cantly stimulated DNA synthesis in PS200 cells (Figure 4a ). Similar results were obtained with media conditioned by cells transiently transfected either with the wild type pcDNA3.1-T94796 (WT) or with the mutant P5 construction, compared to control empty vector transfected cells media (C) (Figure 4b) . Moreover, the addition of 1 mg/ml of anti-PDGFB antibodies to stable clones supernatants as well as to transient transfected cells media, notably neutralized this mitogenic eect (Figure 4a ,b, lanes +). It is of note that supernatants from both wild type (WT) and uncleaved P5 mutated COL1A1 ± PDGFB transient transfected cells had a similar mitogenic eect on PS200 cells (Figure 4b ).
These ®ndings suggest that the secreted proteins produced by COL1A1 ± PDGFB transfected cells in the extracellular medium act as potent mitogens. The fact that anti-PDGFB antibodies neutralize this mitogenic eect may indicate that the secreted PDGFB dimers produced by the COL1A1 ± PDGFB cleavage are responsible for cell growth stimulation. However, when COL1A1 ± PDGFB protein remained uncleaved (P5 mutation), the mitogenic eect persists and is neutralized by addition of anti-PDGFB antibodies. One hypothesis is that uncleaved 116 kD COL1A1 ± PDGFB dimers, as well as cleaved mature PDGFB dimers, are mitogenic factors.
Activation of PDGF b-receptor pathway
The above results indicate that COL1A1 ± PDGFB expressing cells produced mitogenic factors, including PDGFB, responsible for cell growth stimulation. To examine the possibility of the existence of an autocrine stimulation mechanism we tested the PDGF breceptors involvement in COL1A1 ± PDGFB stably transfected clones. Western blot analysis revealed that PDGF b-receptors immuno-precipitated from stable clones XI and XVI cells are expressed as constitutively phosphorylated activated molecules (Figure 5a ). In addition, we showed that media conditioned by transient COL1A1 ± PDGFB transfected HEK293 cells signi®cantly stimulated the activation of PS200 PDGF b-receptors, compared to commercial PDGFB stimulation (Figure 5b ). Supernatants from both wild type (WT) and uncleaved (P5) mutated COL1A1 ± PDGFB transient transfected cells had a similar positive eect on the activation of the control PS200 cells PDGF breceptors. These results suggest that the mitogenic factors, including PDGFB and uncleaved dimers of 116 kD chains, produced by the COL1A1 ± PDGFB transfected cells, stimulate ®broblastic cell growth in an autocrine or paracrine way, through activation of PDGF b-receptors.
Tumourigenicity of COL1A1 ± PDGFB expressing cells
We next evaluated the malignant transformation potential of COL1A1 ± PDGFB expressing cells, in testing their ability to develop tumours in nude mice. Mice were sub-cutaneously injected with 2610 6 cells of each separate cell population and the results of tumour formation are summarized in Table 1 . In contrast to the control PS200 cell line and to the control empty vector clone (Co), stable COL1A1 ± PDGFB transfected clones XI and XVI formed tumours within four to six weeks after injection. The cells obtained from the tumours expressed COL1A1 ± PDGFB proteins and retained their ability to grow in a FCS independent manner. Preliminary histological analysis indicated that tumours displayed a phenotype similar to that of human DP. H-thymidine incorporation into growth-arrested PS200 control cells exposed during 24 h to increasing concentrations of conditioned media from stable transfected clones XI and XVI or pcDNA 3.1 empty vector control clone (Co) in the absence (7) or in the presence (+) of 1 mg/ml of anti-PDGFB neutralizing antibodies. (b) 3 H-thymidine incorporation into growth-arrested PS200 control cells exposed for 24 h to increasing concentrations of media conditioned by HEK293 cells transiently transfected with pcDNA 3.1 empty vector (C) or with wild type (WT) and mutant (P5) COL1A1 ± PDGFB pcDNA3.1 ± T94796 constructs in the absence (7) or in the presence (+) of 1 mg/ml of anti-PDGFB neutralizing antibodies
Discussion
We previously demonstrated that the DP-associated translocation t(17;22), which results in the fusion of the COL1A1 gene to the PDGFB gene, leads to the production of chimeric COL1A1 ± PDGFB RNA in DP tumour cells. In all tested cases, the same PDGFB sequence was juxtaposed in frame to a variable COL1A1 fragment. Sequences analyses showed that COL1A1 ± PDGFB putative proteins displayed a peculiar pro-peptide structure, which preserved the Nterminal COL1A1 pro-peptide containing the signal peptide and the N and C-terminal PDGFB maturation cleavage sites. We thus hypothesized that the COL1A1 ± PDGFB RNA produced in DP cells encoded COL1A1 ± PDGFB pro-peptides that are further processed into mature PDGFB. This uncontrolled PDGFB production could participate in DP development by creating an autocrine cell stimulation mechanism. To test this hypothesis, we stably transfected a DP-derived cDNA bearing a COL1A1 ± PDGFB fusion sequence in ®broblastic PDGF b-receptor expressing PS200 cells (Meloche et al., 1992a,b) .
Our results demonstrated that transfected cell lines, expressing the tumour derived T94796 ± COL1A1 ± PDGFB sequence became independent of growth factors, including PDGFB, and induced tumour formation in nude mice. Using speci®c anti-COL1A1 ± PDGFB and anti-PDGFB antibodies we showed that COL1A1 ± PDGFB expressing cells produced 116 kD chimeric COL1A1 ± PDGFB chains, which probably formed dimers and were processed to give a number of cleavage products, including 30 kD PDGFB-like secreted components. These latter species could correspond to those previously characterized in studies on PDGFB processing (Ostman et al., 1992) . Indeed, PDGFB is produced as 56 kD PDGFB precursor dimers ®rst cleaved at the N-terminal level to give cell-associated 40 kD dimers. A second cleavage on the C-terminal side releases secreted 30 kD mature dimers. Taken together, the data led us to propose that the COL1A1 ± PDGFB chimeric proteins expressed in COL1A1 ± PDGFB transfected cells, are processed to give active PDGFB-like dimers. In addition, we showed that the COL1A1 ± PDGFB stable clones contained activated PDGF b-receptors and that the conditioned media from COL1A1 ± PDGFB transfected cells were able to stimulate PS200 cell growth. Anti-PDGFB antibodies neutralized this eect. We thus established that COL1A1 ± PDGFB transfected clones produced PDGFB-like molecules that could stimulate cell growth in an autocrine or paracrine way through PDGF b-receptors activation.
To prove that the PDGFB-like species detected in COL1A1 ± PDGFB transfected cells are eectively produced by COL1A1 ± PDGFB protein cleavage, we mutated the COL1A1 ± PDGFB putative proteolytic cleavage sites, including the PDGFB maturation sites. The eects of the mutations were tested in transient transfection experiments using the HEK293 cell line. Our results not only con®rmed that COL1A1 ± PDGFB transfected cells produced PDGFB-like growth factors in media but also de®nitely demonstrated that these PDGFB-like molecules directly resulted from the proteolysis of the COL1A1 ± PDGFB fusion proteins.
Ours results are rather similar but at variance with those published by Greco et al., (1998) and Shimizu et al., (1999) . Greco et al showed that COL1A1 ± PDGFB expressing cells produced a PDGFB-like activity clearly involved in cell transformation but they did not demonstrate the presence of either mature PDGFB or chimeric COL1A1 ± PDGFB precursor proteins in COL1A1 ± PDGFB transfected cells. Shimizu et al showed the production of a chimeric COL1A1 ± PDGFB protein and the accumulation of cell-associated 40 kD and 24 kD PDGFB forms in COL1A1 ± PDGFB transfected cells, suggesting that the chimeric COL1A1 ± PDGFB protein was processed in these cells as is also wild type PDGFB. However, they did not detect PDGFB secreted molecules in cell media. Our results not only provide the evidence that the chimeric COL1A1 ± PDGFB protein was processed in COL1A1 ± PDGFB transfected cells to give PDGFBlike molecules but also demonstrated the presence of a 30 kD secreted PDGFB form in COL1A1 ± PDGFB expressing cell media. Moreover, mutagenesis experiments suggested that unprocessed chimeric COL1A1 ± PDGFB species could also play a role in cell growth stimulation. Surprisingly, when the cleavage of the COL1A1 ± PDGFB fusion proteins was prevented as well as the release of PDGFB in cells, the mitogenic potential of the produced molecules was not modi®ed. Although we could not completely exclude the presence of non-speci®c cleavages of COL1A1 ± PDGFB and the production of atypical but active PDGFB forms, this could mean that whole uncleaved chimeric COL1A1 ± PDGFB dimers could act as mitogenic factors. Indeed, we could expect that as for PDGFC, a newly described protease-activated PDGF family member (Li et al., 2000) , the N-terminal collagen domain of the chimeric COL1A1 ± PDGFB protein inhibited its mitogenic function. PDGFC is a secreted protein and has a remarkable two-domain structure not previously observed in this family of growth factors, with a Nterminal CUB domain and a C-terminal PDGF domain. Whole PDGFC is non functional and the PDGF domain is activated by proteolytic cleavage of the CUB domain. The CUB domain is present in several membrane-bound and secreted proteins and it has been hypothesized that the CUB domain of PDGFC may bind to the pericellular matrix as well as having an inhibitory function in receptor binding and activation. In contrast, in our model, the Nterminal collagen domain of COL1A1 ± PDGFB did not seem to inhibit the PDGF activity.
The fact that the whole unprocessed COL1A1 ± PDGFB chimera remains able to activate PDGF b receptors and to stimulate cell proliferation could suggest that the production of mature PDGFB is not necessary for its mitogenic potential. However, except when the normal proteolytic cleavage was prevented by mutation, the full 116 kD COL1A1 ± PDGFB chimeric chain produced in T94796-cDNA transfected cells was not detected in the extracellular media and seems to be processed into the intracellular cell compartment to give secreted mature PDGFB dimers. Thus, if the whole COL1A1 ± PDGFB protein activates PDGF breceptors in COL1A1 ± PDGFB stably transfected cells, we should hypothesize that it occurs in an intracellular way as is assumed in v-sis transformed cells (Fleming et al., 1989) . The PDGF b-receptors pathway would be activated in a classical autocrine or paracrine way as well as by an intracellularly mode. Both cleaved and uncleaved forms of the chimeric PDGFB proteins could concur in uncontrolled COL1A1 ± PDGFB cells growth.
In conclusion, our results suggest that COL1A1 ± PDGFB chimeric gene expression associated with DP, induced tumour formation through the ectopic production of PDGFB expressed as both chimeric COL1A1 ± PDGFB and mature forms.
What could be the role played by the collagen sequences? The simplest hypothesis is that COL1A1 sequences act as a driver for PDGFB expression. In DP cells, the t(17;22) results in the juxtaposition of a COL1A1 fragment to PDGFB and in the loss of the negative regulators of PDGFB transcription and translation. This is also the case in the simian sarcoma virus model where the v-sis activated oncogene lacks the regulatory sequences. In DP, an active COL1A1 promoter and COL1A1 exons replace the PDGFB negative regulatory elements and results in the production of a high level of chimeric COL1A1 ± PDGFB mRNAs. In this context, the t(17;22) rearrangement present in DP, could be considered as a novel way to activate the expression of PDGFB.
The COL1A1 domain of the chimeric protein also provides the signal peptide, which is a prerequisite for the correct export of the protein. The wide size variation of the collagen domain juxtaposed to the PDGFB domain in the various chimeric proteins so far identi®ed indicate that the collagen sequence would not play a crucial role in the COL1A1 ± PDGFB growth factor activity. The fact that the full chimeric COL1A1 ± PDGFB structure has preserved mitogenic action via the PDGF b-receptors suggests that the PDGFB entity of the chimera behaves as an independent growth factor domain.
Additionally, two previous reports have provided convincing evidence for direct activation of Discoidin Domain Receptor tyrosine kinase DDR1 and DDR2, by various collagens including type 1 collagen (Shrivastava et al., 1997; Vogel et al., 1997) . Moreover, DDR1 and DDR2 were found to be over-expressed in a variety of human primary tumours, suggesting that these receptors might play a role in the tumours formation (Alves et al., 1995) . Remarkably, we showed that the processing of the chimeric T94796 COL1A1 ± PDGFB protein into PDGFB dimers also resulted in the production of signi®cant quantities of 100 kD collagen-like components in the extracellular medium. These molecules are mainly composed by the Nterminal collagen fragment of the chimeric COL1A1 ± PDGFB protein and retain the putative proteolytic cleavage site, which corresponds to the COL1A1 chain N-terminus propeptide removal during collagen ®bre formation. In fact, the COL1A1 chains, associated as trimers with COL1A2 chains, are secreted in the extracellular medium and are cleaved at the N-and C-termini before they form mature collagen ®bres (Royce and Steinmann, 1993) . Thus, we could imagine that the 100 kD collagen-like molecules could be processed in the extracellular medium and could participate in anomalous collagen ®bres formation. In this context the study of DDR1 and DDR2 activation in COL1A1 ± PDGFB expressing cells constitutes an attractive research objective. Several mechanisms could concur in the establishment of a transformed phenotype in DP-COL1A1 ± PDGFB expressing cells: one, the more likely, through the activation of the PDGF b-receptor pathway by over expressing either mature PDGFB or whole chimeric COL1A1 ± PDGFB chains, the second more hypothetical, through DDR activation by producing high quantities of collagen-like structures.
Materials and methods
Cells lines
PS200 cells, a derivative of the established Chinese hamster lung ®broblast cell line CCL39 de®cient in Na + /H + exchange activity, and the human kidney epithelial cell line HEK293 were maintained in Dulbecco's modi®ed Eagle's medium (DMEM) containing 7.5% of foetal calf serum (FCS) or 8% inactivated FCS, respectively.
COL1A1 ± PDGFB cDNA isolation and establishment of PS200 cell lines
In T94796 tumour cells, the t(17;22) translocation resulted in the fusion of COL1A1 exon 29 to PDGFB exon 2 (Simon et al., 1997) . A chimeric COL1A1 ± PDGFB cDNA containing the COL1A1 coding sequences from exon1 to exon 29, fused in frame to PDGFB coding sequences from exon 2 to exon 6 was isolated from DP T94796 RNA by one step RT-PCR (Titan one tube RT ± PCR system, ROCHE, Germany) with the two following primers: COLE: 5'-CGGAATTCATGTT-CAGCTTTGTGGACCTC; PDGFBE: 5'-CGGAATTCC-TAGGCTCCAAGGGTCTCCTT.
After EcoRl digestion the PCR products were puri®ed in an agarose gel and cloned into the mammalian expression vector pcDNA 3.1 (Invitrogen, The Netherlands) in the EcoRl site (Figure 1a ). This construct named pcDNA3.1 ± T94796 was ®rst translated in the presence of 35 S methionine, in a rabbit reticulocyte lysate (Promega, WI, USA), and coded for a predictable 116 kD size COL1A ± PDGFB polypeptide chain (data not shown).
A stable population of PS200 cells expressing the chimeric COL1A1 ± PDGFB cDNA construction was obtained by using the Na + /H + exchanger expression vector NHE-1 as a selective marker. PS200 cells were co-transfected (ratio=1/20) by CaPO 4 precipitation, with the PEAP expression vector (NHE ± 1cDNA) and the pcDNA3.1 expression vector, alone or containing the wild type COL1A1 ± PDGFB cDNA construction (pcDNA3.1-T94796). The transfected cells were selected by acid loading test as previously described (Sardet et al., 1989; Pages et al., 1993) and maintained in culture medium containing 0.5 mg/ml of neomycine.
Genomic DNA was obtained using a standard protocol and digested with Pstl or HindIII. The genomic chimeric COL1A1 ± PDGFB sequence integration was con®rmed by Southern blot analysis using the T94796 cDNA insert as probe. Total RNA was extracted from the transfected cells using the`RNA Insta-Pure' system (Eurogentec, Belgium) and COL1A1 ± PDGFB expression was analysed by one-step RT ± PCR (Titan one tube RT ± PCR system, Roche) with the two following primers: COLVAL: 5'-ATGTTCAGC-TTTGTGGACCTC; PDGFBVAL; 5'-GGCTCCAAGGGT-CTCCTTCA.
RT ± PCR analysis showed that about 20 pcDNA3.1-T94796 stably transfected PS200 clones were expressing the T94796 ± COL1A1 ± PDGFB chimeric sequence. Southern blot experiments showed that these clones had integrated the chimeric sequence at the genomic level. Two independent COL1A1 ± PDGFB transfected clones expressing the chimeric COL1A1 ± PDGFB protein (clones XI and XVI) were chosen for further analysis. One pcDNA3.1 empty vector transfected clone was selected as a control (clone Co).
Mutant COL1A1 ± PDGFB cDNA generation and transient transfection assay
The C5 and P5 COL1A1 ± PDGFB mutant cDNA constructions were directly generated from the wild type pcDNA3.1-T94796 vector using the`Quick Change' site-directed mutagenesis kit (Stratagene, The Netherlands). Base substitutions were con®rmed by sequencing on the A310 sequencer using the ABI PRISM dye terminator (PE Biosystems, England). The wild type pcDNA3.1 ± T94796 (WT) and the mutant constructions C5 and P5 were transiently transfected by CaPO 4 precipitation in HEK293 cell line. The pcDNA3.1 empty vector and the pFGFP vector (expressing the GFP protein) were used as a control.
Conditioned media
Conditioned media were obtained by incubating transiently or stably COL1A1 ± PDGFB transfected cells in media without serum for 24 ± 48 h. The media were then concentrated (up to 1006) on`ultrafree' centrifugal ®lter unit biomax 5 (Millipore, France) and immediately tested on growing PS200 cells.
Reinitiation of DNA synthesis
Cells were seeded in 24 or 96 wells culture plates. When con¯uent, the cells were deprived of growth factors for 24 h. Then, they were stimulated with increasing concentrations of FCS, PDGFB (TEBU, France) or concentrated conditioned media. Methyl 3 H thymidine (Pharmacia Biothec, Europe) at 0.5 m Ci/ml was added alone or in the presence of neutralizing anti-PDGFB antibodies (R&D systems, UK) at 1 mg/ml. After 24 h of incubation, the incorporated radioactivity in acid-precipitable material was measured by liquid scintillation spectrometry.
Tumourigenicity assay
Freshly trypsinised cells were resuspended in 0.5 ml of serumfree medium and cells were injected subcutaneously to ®ve week-old nude mice. 2610 6 PS200 cells from cell lines expressing the empty vector (pcDNA 3.1) or T94796 ± COL1A1 ± PDGFB fusion sequence (clones XI and XVI) were each injected into ®ve nude mice. 2610 6 PS200 nontransfected cells were also injected into ®ve nude mice, as an additional control. Tumours were removed from mice and, after collagenase treatment the cells were plated and maintained in culture for two weeks.
Western blot analysis
Con¯uent cells were lysed either with 2X Laemmli sample buer, or in 1% Triton-X100 lysis buer containing 100 mM NaCl, 50 mM Tris/HCl (pH 7.5), 5 mM EDTA, 50 mM NaF, 0.2 mM orthovanadate, 1 mM PMSF, 1 mM aprotinine, 1 mM leupeptine and 1 mM pepstatin. Immunoprecipitations with anti-PDGF b-receptor antibodies (UBI, NY, USA) were performed in Triton-X100 lysis buer as described by the manufacturer. Total lysates or immunoprecipitated protein samples were resolved on SDS polyacrylamide gel and transferred to nylon membranes (Immobilon-P, Millipore, USA). Membranes were then probed with appropriate antibodies. Immunoreactive proteins were detected by enhanced chemiluminescence after incubation with horseradish peroxidase-conjugated secondary antibodies.
Anti-phosphotyrosine and anti-PDGF b-receptor antibodies were purchased from UBI. Anti-PDGFB antiserum, a gift from Dr Carl-Henrik Heldin recognizes only non-reduced PDGFB forms. To distinctively detect the T94796 ± COL1A1 ± PDGFB fusion protein, we used a speci®c anti-COL1A1 ± PDGFB antiserum obtained as follows: a 138 bp cDNA, containing the T94796 ± COL1A1 ± PDGFB fusion junction sequence (COL1A1 exons 28 and 29 fused to PDGFB exon 2), was cloned in pGEX-5X-1 (Pharmacia Biotech). The GST ± COL1A1 ± PDGFB fusion protein obtained from this construction was puri®ed on a polyacrylamide gel and rabbit immunization was performed by Eurogentec laboratory. The speci®city of the anti-COL1A1-PDGFB serum obtained after immunization was checked by Western blotting. The anti-COL1A1 ± PDGFB serum did not recognize COL1A1 or PDGFB but the speci®c COL1A1 ± PDGFB junction only.
